SI20057A - Vodna suspenzija za intranazalno uporabo - Google Patents

Vodna suspenzija za intranazalno uporabo Download PDF

Info

Publication number: SI20057A
Authority: SI; Slovenia
Prior art keywords: aqueous suspension; suspension; loteprednol etabonate; mixture; microcrystalline cellulose
Prior art date: 1997-01-16

Application number

SI9820018A

Other languages

English (en)

Slovenian (sl)

Inventor

Koji Doi

Original Assignee

Bodor Nicholas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-16

Filing date

1998-01-14

Publication date

2000-04-30

1998-01-14 Application filed by Bodor Nicholas filed Critical Bodor Nicholas

2000-04-30 Publication of SI20057A publication Critical patent/SI20057A/sl

Links

239000007900 aqueous suspension Substances 0.000 title claims abstract description 39
DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims abstract description 29
229960003744 loteprednol etabonate Drugs 0.000 claims abstract description 28
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 10
239000000203 mixture Substances 0.000 claims description 26
239000011734 sodium Substances 0.000 claims description 16
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
229910052708 sodium Inorganic materials 0.000 claims description 14
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 11
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 11
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 11
229950008138 carmellose Drugs 0.000 claims description 11
206010061218 Inflammation Diseases 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
210000002850 nasal mucosa Anatomy 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 3
230000007815 allergy Effects 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 2
229960001798 loteprednol Drugs 0.000 claims 1
239000000725 suspension Substances 0.000 abstract description 26
239000002245 particle Substances 0.000 abstract description 5
238000004220 aggregation Methods 0.000 abstract description 4
230000002776 aggregation Effects 0.000 abstract description 4
230000014759 maintenance of location Effects 0.000 abstract description 4
230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
238000001556 precipitation Methods 0.000 abstract description 3
230000003266 anti-allergic effect Effects 0.000 abstract description 2
230000007774 longterm Effects 0.000 abstract description 2
230000006641 stabilisation Effects 0.000 abstract description 2
238000011105 stabilization Methods 0.000 abstract description 2
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002500 effect on skin Effects 0.000 abstract 1
231100000017 mucous membrane irritation Toxicity 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
150000001875 compounds Chemical class 0.000 description 15
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
-1 polyoxyethylene Polymers 0.000 description 8
238000002360 preparation method Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
239000013078 crystal Substances 0.000 description 6
230000007794 irritation Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
229940068968 polysorbate 80 Drugs 0.000 description 6
235000011187 glycerol Nutrition 0.000 description 5
239000007921 spray Substances 0.000 description 5
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
229960000686 benzalkonium chloride Drugs 0.000 description 4
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
229920000609 methyl cellulose Polymers 0.000 description 4
239000001923 methylcellulose Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000654 additive Substances 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
239000004359 castor oil Substances 0.000 description 3
235000019438 castor oil Nutrition 0.000 description 3
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000007923 nasal drop Substances 0.000 description 3
229940100662 nasal drops Drugs 0.000 description 3
229940097496 nasal spray Drugs 0.000 description 3
239000007922 nasal spray Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
150000008051 alkyl sulfates Chemical class 0.000 description 2
230000009285 allergic inflammation Effects 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
229960001950 benzethonium chloride Drugs 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
239000003093 cationic surfactant Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000006196 drop Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
LSXOYNURBQLXRV-UHFFFAOYSA-N 4-(chloromethoxy)phenol Chemical compound OC1=CC=C(OCCl)C=C1 LSXOYNURBQLXRV-UHFFFAOYSA-N 0.000 description 1
PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229940046978 chlorpheniramine maleate Drugs 0.000 description 1
229960002689 clemastine fumarate Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229950009769 etabonate Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229960003630 ketotifen fumarate Drugs 0.000 description 1
YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
UEHLXXJAWYWUGI-UHFFFAOYSA-M nitromersol Chemical compound CC1=CC=C([N+]([O-])=O)C2=C1O[Hg]2 UEHLXXJAWYWUGI-UHFFFAOYSA-M 0.000 description 1
229940118238 nitromersol Drugs 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000013112 stability test Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
229960000654 sulfafurazole Drugs 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
229960000351 terfenadine Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
229920001664 tyloxapol Polymers 0.000 description 1
229960004224 tyloxapol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

SI9820018A 1997-01-16 1998-01-14 Vodna suspenzija za intranazalno uporabo SI20057A (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP1966497		1997-01-16
PCT/JP1998/000108 WO1998031343A2 (fr)	1997-01-16	1998-01-14	Suspension aqueuse pour administration nasale

Publications (1)

Publication Number	Publication Date
SI20057A true SI20057A (sl)	2000-04-30

Family

ID=12005518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9820018A SI20057A (sl)	1997-01-16	1998-01-14	Vodna suspenzija za intranazalno uporabo

Country Status (32)

Country	Link
US (1)	US6368616B1 (fr)
EP (1)	EP0973501B1 (fr)
KR (1)	KR100471708B1 (fr)
CN (1)	CN1126535C (fr)
AR (1)	AR011773A1 (fr)
AT (1)	ATE249205T1 (fr)
AU (1)	AU730953C (fr)
BR (1)	BR9806771A (fr)
CA (1)	CA2278025C (fr)
CZ (1)	CZ294919B6 (fr)
DE (1)	DE69818026T2 (fr)
DK (1)	DK0973501T3 (fr)
EA (1)	EA001775B1 (fr)
ES (1)	ES2206880T3 (fr)
HU (1)	HU226613B1 (fr)
ID (1)	ID21892A (fr)
IL (1)	IL130979A0 (fr)
LT (1)	LT4677B (fr)
LV (1)	LV12449B (fr)
MX (1)	MXPA99006628A (fr)
NO (1)	NO324619B1 (fr)
NZ (2)	NZ336990A (fr)
PL (1)	PL190753B1 (fr)
PT (1)	PT973501E (fr)
RS (1)	RS49701B (fr)
SI (1)	SI20057A (fr)
SK (1)	SK283164B6 (fr)
TR (1)	TR199901663T2 (fr)
TW (1)	TW503113B (fr)
UA (1)	UA52722C2 (fr)
WO (1)	WO1998031343A2 (fr)
ZA (1)	ZA98303B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI243687B (en)	1998-04-21	2005-11-21	Teijin Ltd	Pharmaceutical composition for application to mucosa
US6428805B1 (en)	1998-08-26	2002-08-06	Teijin Limited	Powdery nasal compositions
DE19947235A1 (de) *	1999-09-30	2001-04-05	Asta Medica Ag	Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten
AR026073A1 (es)	1999-10-20	2002-12-26	Nycomed Gmbh	Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) *	2000-01-31	2003-05-20	Schering-Plough Healthcare Products, Inc.	Spray composition with reduced dripping
RU2358699C2 (ru) *	2001-06-18	2009-06-20	Ноувен Фамэсьютикэлз, Инк.	Композиция для чрескожной доставки лекарственного средства (варианты), способ ее получения и использование
GB2389530B (en)	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
US7811606B2 (en) *	2003-04-16	2010-10-12	Dey, L.P.	Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) *	2003-04-16	2017-11-07	Mylan Specialty Lp	Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en)	2003-04-16	2014-12-16	Mylan Pharmaceuticals Inc.	Formulations and methods for treating rhinosinusitis
JP4893305B2 (ja)	2003-06-19	2012-03-07	ボーダー、ニコラス・エス	局所又は他の局部投与用のソフト抗炎症性ステロイドの活性及び／又は作用持続性の増強
US7419971B2 (en) *	2003-06-19	2008-09-02	Bodor Nicholas S	Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
US20050095205A1 (en) *	2003-10-31	2005-05-05	Ramesh Krishnamoorthy	Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
BRPI0509220A (pt)	2004-03-25	2007-09-04	Bausch & Lomb	método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
US20070099883A1 (en) *	2005-10-07	2007-05-03	Cheryl Lynn Calis	Anhydrous mometasone furoate formulation
WO2007058935A2 (fr) *	2005-11-14	2007-05-24	Bausch & Lomb Incorporated	Composition ophtalmique pour le traitement de l'oeil sec
US7687484B2 (en) *	2006-05-25	2010-03-30	Bodor Nicholas S	Transporter enhanced corticosteroid activity
US7691811B2 (en) *	2006-05-25	2010-04-06	Bodor Nicholas S	Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
WO2012119261A1 (fr) *	2011-03-10	2012-09-13	Biocia Inc.	Composition de mucus artificiel améliorée comprenant du hyaluronane pour le traitement de la rhinite
AU2012312816A1 (en)	2011-09-22	2014-04-24	Bausch & Lomb Incorporated	Ophthalmic gel compositions
RS65380B1 (sr)	2017-08-24	2024-04-30	Novo Nordisk As	Glp-1 kompozicije i njihova upotreba
CN115135305B (zh)	2020-02-18	2025-09-12	诺和诺德股份有限公司	药物制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5540930A (en) *	1993-10-25	1996-07-30	Pharmos Corporation	Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0709099A3 (fr)	1994-09-28	1996-07-24	Senju Pharma Co	Suspension aqueuse nasale comprenant cyclodextrine
KR100508227B1 (ko)	1997-03-14	2006-03-23	센주 세이야꾸 가부시키가이샤	로테프레드놀에타보네이트수성현탁액

1998
- 1998-01-06 TW TW087100103A patent/TW503113B/zh not_active IP Right Cessation
- 1998-01-14 DE DE69818026T patent/DE69818026T2/de not_active Expired - Fee Related
- 1998-01-14 DK DK98900360T patent/DK0973501T3/da active
- 1998-01-14 TR TR1999/01663T patent/TR199901663T2/xx unknown
- 1998-01-14 PL PL334614A patent/PL190753B1/pl not_active IP Right Cessation
- 1998-01-14 NZ NZ336990A patent/NZ336990A/xx unknown
- 1998-01-14 CN CN98803402A patent/CN1126535C/zh not_active Expired - Fee Related
- 1998-01-14 SK SK948-99A patent/SK283164B6/sk not_active IP Right Cessation
- 1998-01-14 ES ES98900360T patent/ES2206880T3/es not_active Expired - Lifetime
- 1998-01-14 AU AU54952/98A patent/AU730953C/en not_active Ceased
- 1998-01-14 UA UA99084658A patent/UA52722C2/uk unknown
- 1998-01-14 HU HU0002473A patent/HU226613B1/hu not_active IP Right Cessation
- 1998-01-14 KR KR10-1999-7006440A patent/KR100471708B1/ko not_active Expired - Fee Related
- 1998-01-14 IL IL13097998A patent/IL130979A0/xx not_active IP Right Cessation
- 1998-01-14 EP EP98900360A patent/EP0973501B1/fr not_active Expired - Lifetime
- 1998-01-14 ZA ZA98303A patent/ZA98303B/xx unknown
- 1998-01-14 MX MXPA99006628A patent/MXPA99006628A/es not_active IP Right Cessation
- 1998-01-14 ID IDW990725A patent/ID21892A/id unknown
- 1998-01-14 NZ NZ509908A patent/NZ509908A/xx unknown
- 1998-01-14 BR BR9806771-0A patent/BR9806771A/pt not_active IP Right Cessation
- 1998-01-14 AT AT98900360T patent/ATE249205T1/de not_active IP Right Cessation
- 1998-01-14 RS YUP-361/99A patent/RS49701B/sr unknown
- 1998-01-14 PT PT98900360T patent/PT973501E/pt unknown
- 1998-01-14 CA CA002278025A patent/CA2278025C/fr not_active Expired - Fee Related
- 1998-01-14 WO PCT/JP1998/000108 patent/WO1998031343A2/fr active IP Right Grant
- 1998-01-14 EA EA199900659A patent/EA001775B1/ru not_active IP Right Cessation
- 1998-01-14 US US09/341,522 patent/US6368616B1/en not_active Expired - Fee Related
- 1998-01-14 CZ CZ19992374A patent/CZ294919B6/cs not_active IP Right Cessation
- 1998-01-14 SI SI9820018A patent/SI20057A/sl not_active IP Right Cessation
- 1998-01-16 AR ARP980100191A patent/AR011773A1/es active IP Right Grant
1999
- 1999-07-13 NO NO19993453A patent/NO324619B1/no not_active IP Right Cessation
- 1999-07-15 LV LVP-99-109A patent/LV12449B/en unknown
- 1999-08-12 LT LT99-100A patent/LT4677B/lt not_active IP Right Cessation

Also Published As

Publication number	Publication date
LV12449A (lv)	2000-04-20
AU5495298A (en)	1998-08-07
AU730953C (en)	2002-02-07
EA001775B1 (ru)	2001-08-27
US6368616B1 (en)	2002-04-09
CN1250370A (zh)	2000-04-12
MXPA99006628A (es)	2005-01-10
WO1998031343A2 (fr)	1998-07-23
HUP0002473A3 (en)	2001-01-29
NZ509908A (en)	2004-12-24
DE69818026T2 (de)	2004-07-08
YU36199A (sh)	2002-09-19
TW503113B (en)	2002-09-21
BR9806771A (pt)	2000-05-16
CN1126535C (zh)	2003-11-05
TR199901663T2 (xx)	1999-09-21
CZ237499A3 (cs)	2000-01-12
NO324619B1 (no)	2007-11-26
RS49701B (sr)	2007-12-31
PT973501E (pt)	2004-02-27
SK283164B6 (sk)	2003-03-04
HUP0002473A2 (hu)	2000-12-28
PL334614A1 (en)	2000-03-13
HK1026138A1 (en)	2000-12-08
NZ336990A (en)	2001-03-30
UA52722C2 (uk)	2003-01-15
EA199900659A1 (ru)	2000-02-28
KR20000070214A (ko)	2000-11-25
IL130979A0 (en)	2001-01-28
LT4677B (lt)	2000-07-25
LV12449B (en)	2000-09-20
NO993453D0 (no)	1999-07-13
NO993453L (no)	1999-07-13
ZA98303B (en)	1998-07-20
CA2278025A1 (fr)	1998-07-23
CA2278025C (fr)	2005-09-06
EP0973501B1 (fr)	2003-09-10
DE69818026D1 (de)	2003-10-16
ATE249205T1 (de)	2003-09-15
LT99100A (en)	2000-02-25
ID21892A (id)	1999-08-05
HU226613B1 (en)	2009-04-28
ES2206880T3 (es)	2004-05-16
PL190753B1 (pl)	2006-01-31
SK94899A3 (en)	2000-05-16
EP0973501A2 (fr)	2000-01-26
KR100471708B1 (ko)	2005-03-07
DK0973501T3 (da)	2004-01-19
CZ294919B6 (cs)	2005-04-13
AU730953B2 (en)	2001-03-22
AR011773A1 (es)	2000-09-13
WO1998031343A3 (fr)	1998-09-17

Publication	Publication Date	Title
SI20057A (sl)	2000-04-30	Vodna suspenzija za intranazalno uporabo
EP0709099A2 (fr)	1996-05-01	Suspension aqueuse nasale comprenant cyclodextrine
JP6934581B2 (ja)	2021-09-15	エピナスチン又はその塩を含有する水性医薬組成物
EP3593788B1 (fr)	2020-10-28	Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique
US20220370445A1 (en)	2022-11-24	Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
JPH08151332A (ja)	1996-06-11	点鼻用水性懸濁液
JP2022001606A (ja)	2022-01-06	エピナスチン又はその塩を含有する水性組成物
JPH10259132A (ja)	1998-09-29	点鼻用水性懸濁液
HK40030606A (en)	2021-03-05	Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40030606B (en)	2023-01-20	Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890B (en)	2021-05-28	Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890A (en)	2020-10-09	Ophthalmic compositions containing a nitric oxide releasing prostamide
HK1026138B (en)	2004-06-04	Aqueous suspension for nasal administration of loteprednol

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2010-09-30	KO00	Lapse of patent	Effective date: 20100820